JP2014517050A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517050A5
JP2014517050A5 JP2014516318A JP2014516318A JP2014517050A5 JP 2014517050 A5 JP2014517050 A5 JP 2014517050A5 JP 2014516318 A JP2014516318 A JP 2014516318A JP 2014516318 A JP2014516318 A JP 2014516318A JP 2014517050 A5 JP2014517050 A5 JP 2014517050A5
Authority
JP
Japan
Prior art keywords
week
compound
dose
disorder
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014516318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517050A (ja
JP6140151B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/061779 external-priority patent/WO2012175531A1/en
Publication of JP2014517050A publication Critical patent/JP2014517050A/ja
Publication of JP2014517050A5 publication Critical patent/JP2014517050A5/ja
Application granted granted Critical
Publication of JP6140151B2 publication Critical patent/JP6140151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014516318A 2011-06-20 2012-06-20 統合失調症の処置において４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンおよびその塩を投与する方法 Active JP6140151B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161498653P 2011-06-20 2011-06-20
DKPA201100465 2011-06-20
US61/498,653 2011-06-20
DKPA201100465 2011-06-20
PCT/EP2012/061779 WO2012175531A1 (en) 2011-06-20 2012-06-20 Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia

Publications (3)

Publication Number Publication Date
JP2014517050A JP2014517050A (ja) 2014-07-17
JP2014517050A5 true JP2014517050A5 (enExample) 2016-11-17
JP6140151B2 JP6140151B2 (ja) 2017-05-31

Family

ID=58794324

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516318A Active JP6140151B2 (ja) 2011-06-20 2012-06-20 統合失調症の処置において４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンおよびその塩を投与する方法

Country Status (23)

Country Link
US (1) US9610287B2 (enExample)
EP (1) EP2720698B1 (enExample)
JP (1) JP6140151B2 (enExample)
KR (1) KR101900989B1 (enExample)
CN (1) CN103608015A (enExample)
AU (1) AU2012274150B2 (enExample)
BR (1) BR112013032178A2 (enExample)
CA (1) CA2838055C (enExample)
DK (1) DK2720698T3 (enExample)
ES (1) ES2694298T3 (enExample)
HR (1) HRP20181684T1 (enExample)
IL (1) IL230060A (enExample)
JO (1) JO3421B1 (enExample)
LT (1) LT2720698T (enExample)
MX (1) MX349754B (enExample)
PL (1) PL2720698T3 (enExample)
RS (1) RS57944B1 (enExample)
RU (1) RU2613177C2 (enExample)
SI (1) SI2720698T1 (enExample)
SM (1) SMT201800567T1 (enExample)
TW (1) TWI552751B (enExample)
WO (1) WO2012175531A1 (enExample)
ZA (1) ZA201309617B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402400B2 (en) 2001-07-03 2008-07-22 Regents Of The University Of California Mammalian sweet taste receptors
CA2390600A1 (en) 1999-11-17 2001-05-25 Mendel Biotechnology, Inc. Seed trait genes
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
EP1406483A4 (en) 2000-08-22 2005-05-25 Mendel Biotechnology Inc GENE FOR CHANGING THE PROPERTIES OF PLANTS
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
AU2002326315B2 (en) 2001-06-26 2007-07-05 Senomyx, Inc. T1R hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
CA2492883C (en) 2002-08-01 2012-10-02 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
ES2380017T3 (es) 2002-09-18 2012-05-07 Mendel Biotechnology, Inc. Polinucleótidos y polipéptidos en plantas
CN101090729B (zh) 2003-05-30 2014-07-23 艾更斯司股份有限公司 前列腺干细胞抗原(psca)变体及其序列
JP4796967B2 (ja) 2003-11-07 2011-10-19 ヴァーミリオン インコーポレイテッド アルツハイマー病のためのバイオマーカー
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
DK1734996T3 (da) 2004-04-02 2013-06-10 Univ California Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
WO2005118864A2 (en) 2004-05-28 2005-12-15 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
WO2006002262A2 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US7700738B2 (en) 2005-01-27 2010-04-20 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
HRP20181379T1 (hr) 2005-07-19 2018-11-16 Stemgen S.P.A. Inhibiranje tumorogenog potencijala tumorskih matičnih stanica s bmp-4
WO2007047988A2 (en) 2005-10-20 2007-04-26 Senomyx, Inc. Chimeric human sweet-umami and umami-sweet taste receptors
UA94922C2 (ru) 2005-11-07 2011-06-25 Зе Скріпс Рісьорч Інстітьют Способ регулирования специфичности сигнализации тканевого фактора у млекопитающего, которое нуждается в этом, способ идентификации агента, который специфически ингибирует сигнализацию тканевого фактора
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
AU2007227195A1 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and Ly6 E: targets for cancer diagnosis and therapy
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20100292090A1 (en) 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
EP2679999A1 (en) 2006-09-06 2014-01-01 The Regents of the University of California Molecular diagnosis and classification of malignant melanoma
EP2095100B1 (en) 2006-11-22 2016-09-21 President and Fellows of Harvard College Method of operating a nanowire field effect transistor sensor
IN2009KN04568A (enExample) 2007-06-01 2015-08-28 Univ Princeton
US7968293B2 (en) 2007-08-13 2011-06-28 Baxter International Inc. IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
RU2522456C2 (ru) 2007-08-21 2014-07-10 Синомикс, Инк. Соединения, ингибирующие (блокирующие) горький вкус, способы их применения и получения
EA201000343A1 (ru) 2007-10-04 2011-10-31 Займодженетикс, Инк. ЧЛЕН СЕМЕЙСТВА B7, zB7H6 И РОДСТВЕННЫЕ КОМПОЗИЦИИ И СПОСОБЫ
EP2924435A3 (en) 2007-10-22 2015-11-04 The Regents of The University of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
EP2219671A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
SG10202103401QA (en) 2008-03-17 2021-05-28 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
CA2721980C (en) 2008-04-21 2017-01-03 The Regents Of The University Of California Selective high-affinity poly dentate ligands and methods of making such
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
CN102224254A (zh) 2008-09-23 2011-10-19 哈佛大学校长及研究员协会 Sirt4及其用途
EP3260123A1 (en) 2008-11-06 2017-12-27 University of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
EP2352847B1 (en) 2008-11-10 2014-01-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Gene signature for predicting prognosis of patients with solid tumors
AU2009322346B2 (en) 2008-12-03 2015-07-02 The Scripps Research Institute Stem cell cultures
CN102317442B (zh) 2008-12-17 2014-08-13 斯克里普斯研究所 干细胞的产生和保持
US20100291100A1 (en) 2009-03-27 2010-11-18 Gojo Industries, Inc. Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions
AU2010275367B2 (en) 2009-07-24 2015-09-03 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avB5 integrin
CA2771102C (en) 2009-08-14 2019-10-15 The Regents Of The University Of California Methods of diagnosing and treating autism
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2011038228A1 (en) 2009-09-24 2011-03-31 President And Fellows Of Harvard College Bent nanowires and related probing of species
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
EP2825210B1 (en) 2012-03-14 2019-06-26 University of Central Florida Research Foundation, Inc. Lim kinasemodulating agents for neurofibromatoses therapy and methods for screening for same
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
CA2871462A1 (en) 2012-04-24 2013-10-31 University Of Miami Perforin 2 defense against invasive and multidrug resistant pathogens
EP3184121A3 (en) 2012-07-25 2017-09-27 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
DK2954323T3 (da) 2013-02-07 2020-07-20 Univ California Anvendelse af translationsprofilering til identifikation af målmolekyler til terapeutisk behandling
US9428537B2 (en) 2013-03-15 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University tRNA derived small RNAs (tsRNAs) involved in cell viability
EP3080122B1 (en) 2013-12-11 2018-10-31 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015089338A2 (en) 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
WO2015136509A2 (en) 2014-03-14 2015-09-17 Genesis Theranostix Korlatolt Felelossegu Tarsasag Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
US10196701B2 (en) 2015-06-01 2019-02-05 The Penn State Research Foundation Hepatitis B virus capsid assembly
EP3314260B1 (en) 2015-06-24 2021-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for detecting protein-protein interactions
WO2018036503A1 (en) 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
KR20190095355A (ko) 2016-12-15 2019-08-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암의 치료를 위한 조성물 및 방법
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
US12016902B2 (en) 2017-04-04 2024-06-25 Loma Linda University Biologic for the treatment of cancer
US20210247386A1 (en) 2018-04-26 2021-08-12 Technion Research & Development Foundation Limited A device and method for determining cell indentation activity
AU2019373090B2 (en) 2018-10-31 2023-05-25 The University Of Sydney Compositions and methods for treating viral infections
WO2020097261A1 (en) 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and methods for treating beta-globinopathies
US20240301510A1 (en) 2020-11-19 2024-09-12 The Chinese University Of Hong Kong Assessing risk for colorectal adenoma recurrence by noninvasive means
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
US20250092106A1 (en) 2022-01-25 2025-03-20 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2024197185A1 (en) 2023-03-21 2024-09-26 The Broad Institute, Inc. Methods and compositions for dissecting organelle physiology

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
JP5043429B2 (ja) 2003-08-18 2012-10-10 ハー・ルンドベック・アクチエゼルスカベット トランス−４−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−１，２，２−トリメチルピペラジンのコハク酸塩およびマロン酸塩、および薬剤としての使用方法
RU2445095C2 (ru) 2004-04-22 2012-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Новые фармацевтические композиции для лечения сексуальных расстройств
CN103637977A (zh) 2005-07-18 2014-03-19 宾夕法尼亚大学理事会 含药植入物及其使用方法
NZ589571A (en) * 2008-05-07 2012-07-27 Lundbeck & Co As H Method for treating cognitive deficits using trans-4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine
AU2009298264A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
RU2012102247A (ru) * 2009-06-24 2013-07-27 Мсд Осс Б.В. Инъекционные композиции, содержащие асенапин и способ лечения с их применением

Similar Documents

Publication Publication Date Title
JP2014517050A5 (enExample)
RU2014101482A (ru) Способ применения 4-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-1,2,2-триметилпиперазина и его солей в лечении шизофрении
EP3240538B1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
US11058638B2 (en) Tyrosine derivatives and compositions comprising them
JP2021073258A (ja) トラジピタントによる治療方法
JP2015512406A5 (enExample)
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
JP2014502641A5 (enExample)
JP2015524444A5 (enExample)
JP2021080276A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
ES2822562T3 (es) Composiciones intranasales para el tratamiento de enfermedades y trastornos neurológicos y degenerativos
JP2016505050A5 (enExample)
JP2013536206A5 (enExample)
JP2019507786A5 (enExample)
TW201211021A (en) Methods of use of cyclic amide derivatives to treat schizophrenia
JP2012502105A5 (enExample)
JP6830895B2 (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
CN115607545A (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
EP3570841A1 (en) PPARy AGONIST FOR THE TREATMENT OF HUNTINGTON'S DISEASE
JP6420923B1 (ja) 医薬
JP2008143899A (ja) 抵抗性統合失調症およびその他のｃｎｓ疾患の治療
JP2009501205A (ja) 精神病治療用組成物
TW202539621A (zh) 用於治療巴金森氏症的治療劑
KR20200099153A (ko) 외상 후 증후군 장애의 치료
WO2022060978A1 (en) Methods of treating parkinson's disease and related disorders with pde10a inhibitors